AI Predicted Novartis’ $30 Billion Drug Failure. Are Biogen and Takeda Next?
AI startup BioinvestGPT predicted the failure of Novartis AG’s ($NVS) experimental muscular dystrophy drug months before a disappointing Phase 3 re...
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,993,551 | $54,452,693 | -20% | 0.02% |
| 2. | Renaissance Technologies Jim Simons | 2,292,700 | $41,704,213 | -11% | 0.06% |
| 3. | Quantinno Capital Hoon Kim | 1,612,864 | $29,338,003 | +15% | 0.03% |
| 4. | 150,000 | $2,728,500 | 0.12% | ||
| 5. | Fisher Asset Management Ken Fisher | 86,978 | $1,582,139 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.90 | 55,617 | $1,162,395.30 | 270,253 | 2026-11-04 | Filing | |
| $20.89 | 46,609 | $973,662.01 | 214,501 | 2026-11-02 | Filing | |
| $18.54 | 34,535 | $640,278.90 | 191,522 | 2026-09-14 | Filing | |
| $18.49 | 116,191 | $2,148,371.59 | 145,465 | 2026-09-02 | Filing | |
| $18.49 | 19,651 | $363,346.99 | 261,656 | 2026-08-19 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 26,952,673 | $490,269,122 | 0.07% | |
| 2. | 10,974,215 | $199,620,966 | 0.01% | |
| 3. | 8,234,395 | $149,783,668 | 0.01% | |
| 4. | 3,938,925 | $71,649,050 | 0% | |
| 5. | 2,154,887 | $39,197,395 | 0.03% |